If signed into law, H.R. 4116 would mandate pharmaceutical manufacturing companies to report how and why they set drug prices to help bring more transparency to the industry.
Rep. Lloyd Doggett (TX-35) introduced H.R. 4116 on October 25,2017. It has been referred to the House Committee on Energy and Commerce.
Learn more about H.R. 4116 here.